Dr Reddy's Laboratories

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Ajit Mishra of Religare Broking recommends Nifty strategy and two stocks to buy; check details here

Hyderabad-based Dr Reddy's has applied to trademark the Obeda brand and logo, a government filing showed

Dr Reddy's Laboratories has forayed into hormone replacement therapy segment by acquiring trademarks of specialty brands, Progynova and Cyclo-Progynova and related assets, for India from UK-headquartered Mercury Pharma Group for USD 32.15 million, according to a company statement. Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components. As per IQVIA MAT December 2025, the brand recorded sales of Rs 100 crore. The acquisition strengthens Dr Reddy's gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment, the drug firm stated. "The acquisition will serve as the spearhead of our expansion into the HRT segment, ...

Stocks to Watch today, February 19, 2025: Dr Reddy's Labs, Hindustan Unilever, NCC, DLF, and Jindal Saw are some of the key stocks to watch today

In Q3, Dr Reddy's Laboratories reported a 14 per cent year-on-year (Y-o-Y) decline in consolidated net profit to ₹1,210 crore, as compared to ₹1,413 crore a year ago

Stocks to watch on January 16, 2026: Stocks like Infosys, ICICI Prudential AMC, Biocon, Angel One and HDB Financial Services will remain in focus today

According to the agreement, Immutep will receive from Dr Reddy's an upfront payment of $20 million (around AUD 30.2 million)

Over the last few years, Dr Reddy's has diversified its portfolio beyond generics to include cancer therapies as it battles pricing pressures in North America, its largest market

Nomura expects Indian markets to trade in the range of 20-22x one-year forward earnings, assuming risk premia remain low.

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

Stocks to Watch Today, November 25, 2025: Dr. Reddy's Labs, Siemens Energy, HUDCO, Sunteck Realty and other stocks will remain in focus; here's why

Health Canada's non-compliance notice may delay DRL's semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Q2FY26 company results: Many firms including 3p Land Holdings, Covance Softsol, Pace Digitek and Samsrita Labs are also to release their July-September quarter earnings reports today

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulator for its formulations manufacturing facility at Srikakulam in Andhra Pradesh, classifying the facility as voluntary action indicated. The US Food & Drug Administration (USFDA) had conducted a GMP and a Pre-Approval Inspection (PAI) conducted by at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, India, intimated to the exchanges on July 18, 2025, Dr Reddy's Laboratories Ltd said in a regulatory filing. "We wish to inform you that the company has received the Establishment Inspection Report (EIR) on October 20, 2025. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)'," it said, adding the inspection is officially closed. Under voluntary action indicated (VAI), while objectionable conditions were found and documented during an inspection, the agency is not prepared to take or ...

Indian pharma takes Novo Nordisk to court over patents that keep Wegovy and Ozempic out of reach - could this slash prices for millions of patients?

Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US

Dr Reddy's Laboratories' posted a revenue of ₹8,545.2 crore, up 11 per cent year-on-year (Y-o-Y) but flat sequentially.